DOCSLIB.ORG

Notice of Annual General Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Notice of Annual General Meeting This document is important and requires your immediate attention If you are in any doubt as to what action you should take, you should consult immediately with your stockbroker, bank manager, solicitor, accountant or other independent professional adviser authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all your shares in Reed Elsevier PLC, please send this Notice of Annual General Meeting and accompanying documents to the stockbroker, or other agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee. A Form of Proxy for the Annual General Meeting is enclosed and should be completed and returned so as to reach the company’s Registrar by no later than 11.00 am on Monday 21 April 2008. Completion and return of the Form of Proxy will not prevent you from attending and voting at the meeting in person, should you wish. Alternatively, you can register your proxy vote electronically, either by means of a website provided by the company’s Registrar at www.sharevote.co.uk, or by using the service provided by Euroclear UK & Ireland Limited. Further details are given in the notes to the attached Notice of Annual General Meeting. Reed Elsevier PLC Notice of Annual General Meeting to be held at the Millennium Hotel, Grosvenor Square, London, W1K 2HP on Wednesday, 23 April 2008 at 11.00 am 2 Notice of Annual General Meeting To the holders of Reed Elsevier PLC ordinary shares Dear Shareholder, Annual General Meeting 2008 Introduction I am pleased to invite you to the Annual General Meeting of the company for 2008, which will be held on Wednesday, 23 April 2008 at 11.00 am in the Ballroom at the Millennium Hotel, Grosvenor Square, London, W1K 2HP. Dividend The company will be reinstating the Dividend Reinvestment Plan (“DRIP”) for the 2007 final dividend payment of 13.6p per share, payable on 16 May 2008. Shareholders who elected to reinvest their 2007 interim dividend, and who wish to reinvest their 2007 final dividend, need take no action. The closing date for withdrawing a previous dividend reinvestment election, or making a new election, is 2 May 2008. Further information concerning the DRIP appears on page 191 of the Reed Elsevier Annual Reports and Financial Statements 2007. Board appointments Sir Crispin Davis, Andrew Prozes, Lisa Hook and Gerard van de Aast will retire from the board by rotation at the Annual General Meeting and, being eligible, offer themselves for re-election. Biographical information concerning the directors seeking re-election appears on page 7. During the year the Corporate Governance Committee conducted a review of the functioning and constitution of the boards and their committees, and also retained external consultants to conduct a board effectiveness review. Based on these assessments and the board effectiveness review, the Nominations Committee believes that the performance of each director seeking re-election at the Annual General Meeting continues to be effective, and that they each demonstrate commitment to their respective roles in Reed Elsevier. Accordingly, the Nominations Committee recommends the re-election of each director. Special Business Resolutions The Notice of Meeting on pages 8 and 9 sets out, in addition to the items of routine business, the items of special business to be considered at the Annual General Meeting. These items are noted below and explained in more detail on pages 4 to 6. Directors’ Remuneration Report (Resolution 2) In accordance with legislation, shareholders are given the opportunity to vote on the Remuneration Report. In line with the legislation, this vote will be in respect of the content of the Remuneration Report and not specific to any director’s level or terms of remuneration, and will be advisory in nature. Authority to allot and purchase own shares (Resolutions 10, 11 and 12) These items relate to the renewal of the authority previously approved by shareholders to permit the directors, subject to the limits described in the individual Resolutions, to: – allot the unissued share capital in the company; – allot equity securities for cash on a non pre-emptive basis; and – make market purchases of the company’s shares (with the ability to hold the purchased shares in treasury). If approved by shareholders, Resolution 12 will enable the company to continue to operate the annual share repurchase programme, which commenced in 2006. The repurchase of shares in the company and Reed Elsevier NV will reflect the equalisation ratio. Articles of Association (Resolution 13) Resolution 13 concerns the proposed adoption of new Articles of Association, primarily to implement the phased introduction of the Companies Act 2006. The new Articles of Association will, if approved, come into effect in two stages and will allow the company, inter alia, to take advantage of recent legislation regarding electronic communications with shareholders and to take account of other changes in company law. The first group of Notice of Annual General Meeting 3 amendments will come into effect upon approval of the Resolution, to reflect changes in legislation which are already effective. The second group of amendments reflect changes in legislation that will become effective on 1 October 2008. Electronic communications The company is already making use of electronic communications through publishing its results announcements and presentations, trading updates and other important announcements and corporate governance documents concerning Reed Elsevier on its website, www.reedelsevier.com. Many of the company’s shareholders already find it more convenient to access shareholder information by means of the company’s website, and have registered an email address with the company’s Registrar so that they may be advised when shareholder documents have been posted on the company’s website. Increased use of electronic communications, which will be made possible as a result of the changes to the Articles of Association proposed in Resolution 13, will deliver savings to the company in terms of administration, printing and postage costs. It will also speed up the communication of information to shareholders, whilst at the same time delivering significant environmental benefits through reduced use of paper and the energy required for its production and distribution. Any shareholder who prefers to receive shareholder communications in the traditional paper form will still be able to do so. Recommendation Your board considers that the proposed Resolutions set out in the Notice of Meeting are in the best interests of the company and the shareholders as a whole. Accordingly, they unanimously recommend you to vote in favour of each Resolution, as they themselves intend to do in respect of their own shareholdings in the company. Voting procedures Enclosed with the Notice of Meeting is a Form of Proxy. Whether or not you plan to attend the Annual General Meeting, I would ask you to complete the Form of Proxy and return it to the company’s Registrar at the address shown on the Form of Proxy. Alternatively, a proxy vote may be submitted via the Internet at www.sharevote.co.uk or, if you are a user of the CREST system, via the Crest electronic proxy appointment service. Further information concerning the appointment of a proxy is set out on pages 10 and 11. All Resolutions proposed at the meeting will be decided by poll. This reflects best corporate governance practice and will ensure that shareholders who are not able to attend the Annual General Meeting, but who have appointed proxies, have their votes fully taken into account. Yours sincerely Jan Hommen Chairman 20 March 2008 4 Notice of Annual General Meeting Explanation of items of special business to be proposed at the 2008 Annual General Meeting Resolution 2 – Directors’ Remuneration Report Under the Directors’ Remuneration Report Regulations 2002, shareholders are given the opportunity to vote on the Directors’ Remuneration Report. In line with the legislation, this vote will be in respect of the content of the Remuneration Report and not specific to any director’s level or terms of remuneration, and will be advisory in nature. The Directors’ Remuneration Report is contained in the Annual Reports and Financial Statements 2007. Resolution 10 – Allotment of shares This Resolution renews the authority of the directors previously approved by shareholders to allot shares up to the amount of the authorised but unissued share capital in the company, which at 3 March 2008 stood at £20.3 million, representing 12.4% of the total issued ordinary share capital (excluding treasury shares) of the company. Although at present the directors have no intention of exercising the authority, it is considered prudent to maintain the flexibility it provides. Resolution 11 – Disapplication of pre-emption rights This Resolution renews the authority of the directors previously approved by shareholders to allot equity securities for cash without first being required to offer such securities to the then existing shareholders pro rata to their holdings. The first part of the authority relates to the issue of securities of up to a nominal amount of £8 million, representing less than 5% of the company’s issued ordinary share capital. Companies are generally able to allot equity securities for cash in order to satisfy entitlements under their share option schemes without those securities being counted towards that company’s normal 5% disapplication limit. However, as a consequence of the merger of the Reed Elsevier PLC and Reed Elsevier NV businesses in 1993, employees of the company and its subsidiaries became employees of either Reed Elsevier Group plc or a Reed Elsevier participating company. This has the effect that equity securities issued by the company under the Reed Elsevier Group plc share option schemes (which were introduced to operate in place of the schemes operated by the company prior to the merger and which have been approved by shareholders) must, as a matter of law, be counted towards the company’s disapplication limit.
Load more

Recommended publications
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Voting/Poll Results
    GLAXOSMITHKLINE PLC - RESULT OF AGM GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders. GlaxoSmithKline AGM Poll Results The following table shows the votes cast for each resolution: Resolution Total votes % Total votes % Total votes Votes for* against cast withheld** Adoption of Directors’ 1 Report and Financial Statements 3,713,877,875 98.86 42,764,532 1.14 3,756,642,407 9,313,386 Approval of the 2 Remuneration Report 3,528,115,173 94.55 203,482,136 5.45 3,731,597,309 34,358,483 Election of 3 Lynn Elsenhans 3,753,666,422 99.90 3,577,765 0.10 3,757,244,187 8,711,607 Election of 4 Jing Ulrich 3,753,601,642 99.90 3,623,347 0.10 3,757,224,989 8,730,805 Election of 5 Hans Wijers 3,712,833,757 98.82 44,327,830 1.18 3,757,161,587 8,794,257 Re-election of Sir 6 Christopher Gent 3,679,075,355 97.92 78,304,492 2.08 3,757,379,847 8,575,946 Re-election of 7 Sir Andrew Witty 3,753,850,300 99.90 3,750,413 0.10 3,757,600,713 8,355,081 Re-election of Professor Sir 8 Roy Anderson 3,753,929,716 99.91 3,483,857 0.09 3,757,413,573 8,542,221 Re-election of 9 Dr Stephanie Burns 3,749,134,033 99.78 8,228,665 0.22 3,757,362,698 8,592,951 Re-election of 10 Stacey Cartwright 3,735,971,985 99.43 21,360,372 0.57 3,757,332,357 8,623,292 Re-election of 11 Simon Dingemans 3,749,800,702 99.80 7,359,374 0.20 3,757,160,076 8,795,718 Re-election of 12 Judy Lewent 3,746,232,485 99.71 11,060,403 0.29 3,757,292,888 8,662,906 Re-election of 13 Sir Deryck Maughan 3,748,191,348 99.76 9,051,199 0.24
    [Show full text]
  • Corporate Responsibility Report 2008
    Corporate Responsibility Report 2008 Strength through responsibility Summary Reed Elsevier Corporate Responsibility Report 2008 Chief Executive’s introduction Governance People Our true performance as a company must take account of both our non-financial and financial results. They are intrinsically linked – if we want to be a profitable and successful company, we must be an ethical one. We are committed to being both. To that end, we have been building on our expertise and engaging with stakeholders to find ways to innovate and improve. Health and safety In developing online solutions to the needs of our customers in areas like health, science and technology, law, environment, and business, we benefit society. For example, Procedures Consult gives doctors a way of maintaining their skills and knowledge through web-based simulation of essential medical techniques; TotalPatent is a single source for global patents, a primary driver in research and development; XpertHR helps practitioners advance good practice in people management; energylocate aggregates our energy offerings into a one-stop community, using tools like social networking and video to advance knowledge. Customers Innovation is also helping advance our internal corporate responsibility: > Increased online training in our Code of Ethics and Business Conduct has led to more of our people understanding what it means to do the right thing > A new global jobs board illuminates our value, Boundarylessness, by allowing employees to search for new positions across locations, functions,
    [Show full text]
  • 22 November 2012 • No 5007 • Vol 143 Gazette
    ThursdaY 22 november 2012 • no 5007 • vol 143 Gazette Council and Main Notices 179 Advertisements 183 Committees 176 Consultative notices: Council of the University: Consolidation of small trust funds Notifications of Vacancies 186 Approval of nomination of external member of Council General notices: University of Oxford Gazette publication arrangements Council of the University: Colleges, Halls and Societies Changes in Regulations: Appointments: External Vacancies (a) Committees reporting directly to University Administration and Council or one of its main Services Supplement included with this issue: committees (1) to no 5006: Topic for discussion: (b) Regulations for the Student Visiting Professorships: the libraries and their future 159–174 Fitness to Study Panel Medical Sciences (c) Delegacy for Military Instruction (d) Personnel Committee Electoral Boards: (e) Research Committee Professorship of Economics (f) Socially Responsible Investment Newton Abraham Visiting Review Committee Professorship in the Medical, (g) Income grant from the College Biological and Chemical Sciences Contributions Fund Musical and other Events: General Purposes Committee of Council: lincoln Changes in Regulations: Exhibitions: Saïd Business School and Business Magdalen Advisory Council Council of the University: Lectures 181 Register of Congregation Examinations and Boards 181 Congregation 178 Examinations for the Degree of Doctor of Congregation 26 November: Philosophy Degree by Resolution Examinations for the Degree of Master of Congregation 27 november:
    [Show full text]
  • Vote Summary
    Vote Summary FENNER PLC, HESSLE YORKSHIRE Security G33656102 Meeting Type Annual General Meeting Ticker Symbol Meeting Date 14-Jan-2015 ISIN GB0003345054 Agenda 705747369 - Management Record Date Holding Recon Date 12-Jan-2015 City / Country LONDON / United Vote Deadline Date 08-Jan-2015 Kingdom SEDOL(s) 0334505 - B3BH6Q8 Quick Code Proposal Proposed Vote For/Against by Manageme nt Item 1 TO RECEIVE THE REPORTS OF THE DIRECTORS Management For For 2 TO APPROVE THE BOARD REMUNERATION POLICY Management For For 3 TO APPROVE THE BOARD ANNUAL REMUNERATION Management For For 4 TO DECLARE A DIVIDEND Management For For 5 TO RE-ELECT MARK ABRAHAMS Management For For 6 TO RE-ELECT NICHOLAS HOBSON Management For For 7 TO RE-ELECT RICHARD PERRY Management For For 8 TO RE-ELECT VANDA MURRAY Management For For 9 TO RE-ELECT JOHN SHELDRICK Management For For 10 TO RE-ELECT ALAN WOOD Management For For 11 TO RE-APPOINT THE AUDITORS Management For For 12 TO AUTHORISE THE DIRECTORS TO DETERMINE Management For For 13 TO APPROVE THE FENNER PERFORMANCE SHARE Management For For 14 AUTHORITY TO ALLOT SHARES Management For For 15 POWER TO ALLOT SHARES FOR CASH AND Management For For 16 AUTHORITY TO BUY BACK SHARES Management For For 17 TO ALLOW THE COMPANY TO HOLD GENERAL Management For For IMPERIAL BRANDS PLC, BRISTOL Security G4721W102 Meeting Type Annual General Meeting Ticker Symbol Meeting Date 28-Jan-2015 ISIN GB0004544929 Agenda 705751356 - Management Record Date Holding Recon Date 26-Jan-2015 City / Country BRISTOL / United Vote Deadline Date 22-Jan-2015
    [Show full text]
  • FORM N-PX Annual Report of Proxy Voting Record of Registered Management Investment Companies Filed on Form N-PX
    SECURITIES AND EXCHANGE COMMISSION FORM N-PX Annual report of proxy voting record of registered management investment companies filed on Form N-PX Filing Date: 2021-08-13 | Period of Report: 2021-06-30 SEC Accession No. 0000894189-21-005339 (HTML Version on secdatabase.com) FILER HOTCHKIS & WILEY FUNDS /DE/ Mailing Address Business Address 601 SOUTH FIGUEROA 601 SOUTH FIGUEROA CIK:1145022| IRS No.: 000000000 | State of Incorp.:DE | Fiscal Year End: 0630 STREET STREET Type: N-PX | Act: 40 | File No.: 811-10487 | Film No.: 211171831 39TH FLOOR 39TH FLOOR LOS ANGELES CA LOS ANGELES CA 90017-5704 90017-5704 2134301000 Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM N-PX ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-10487 Hotchkis and Wiley Funds -------------------------------------------------------------------------------- (Exact name of registrant as specified in charter) 601 S. Figueroa Street, 39th Floor, Los Angeles, CA 90017 -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Anna Marie Lopez 601 S. Figueroa Street, 39th Floor Los Angeles, CA 90017 -------------------------------------------------------------------------------- (Name and address of agent for service) Registrant's telephone number, including area code: 1-213-430-1000 Date
    [Show full text]
  • Annual Report 2008 Find out More About GSK Online…
    Do more, feel better, live longer Grow Deliver Simplify Annual Report 2008 Find out more about GSK online… www.gsk.com Website GlaxoSmithKline’s website www.gsk.com gives additional information on the Group. Information made available on the website does not constitute part of this Annual Report. Notice regarding limitations on Director liability under English Law Under the UK Companies Act 2006, a safe harbour limits the liability of Directors in respect of statements in and omissions from the Report of the Directors contained on pages 12 to 98. Under English law the Directors would be liable to the company (but not to any third party) if the Report of the Directors contains errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. Report of the Directors Pages 12 to 98 inclusive consist of a Report of the Directors that has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law. Cautionary statement regarding forward-looking statements The Group’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document and written information released, or oral statements made, to the public in the future by or on behalf of the Group, may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. A shareholder can identify these statements by the fact that they do not relate strictly to historical or current facts.
    [Show full text]
  • Printmgr File
    Dear Fellow Shareholders, Hasbro will host the 2017 Annual Meeting of Shareholders on Thursday, May 18 at the Company’s headquarters in Pawtucket, Rhode Island. The attached Notice of Annual Meeting of Shareholders and Proxy Statement provides information regarding the business we will conduct at the Meeting and other important matters regarding our Company. On behalf of Hasbro’s Board of Directors, we encourage you to vote your shares and invite you to join the meeting. Over the past ten years, Hasbro has redefined itself as a global organization Creating the World’s Best Play Experiences. It has invested to build the best possible team to execute consumer insight and story-led brands across consumer touch points, including toys and games, digital gaming, entertainment and consumer products. This strategic roadmap is known as Hasbro’s Brand Blueprint. In 2016, strong execution of the Brand Blueprint delivered another record year. 13% revenue growth drove Hasbro’s first $5 billion revenue year along with a 14% increase in operating profit and a 22% increase in diluted earnings per share. Consistent with Hasbro’s long-standing capital priorities, the Company invested back into the business to drive long-term profitable growth and shareholder value creation. In 2016, this included investing in brands, innovation, new capabilities around the Brand Blueprint, such as the acquisition of Boulder Media, and in systems infrastructure. The Company then returned excess cash to shareholders. Hasbro generated $775 million in operating cash flow last year and returned approximately $400 million to shareholders. This included $249 million in dividends and $151 million in share repurchases.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018
    Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018 Panera Bread Company Meeting Date: 07/11/2017 Proposal Vote Number Proposal Text Instruction 1 Approve Merger Agreement For 2 Advisory Vote on Golden Parachutes Against BT Group plc Meeting Date: 07/12/2017 Proposal Vote Number Proposal Text Instruction Meeting for ADR Holders 1 Accept Financial Statements and Statutory Against Reports 2 Approve Remuneration Report Against 3 Approve Remuneration Policy Against 4 Approve Final Dividend For 5 Re-elect Sir Michael Rake as Director Against 6 Re-elect Gavin Patterson as Director Against 7 Re-elect Simon Lowth as Director Against 8 Re-elect Tony Ball as Director Against 9 Re-elect Iain Conn as Director Against 10 Re-elect Tim Hottges as Director Against 11 Re-elect Isabel Hudson as Director Against 12 Re-elect Mike Inglis as Director Against 13 Re-elect Karen Richardson as Director Against 14 Re-elect Nick Rose as Director Against 15 Re-elect Jasmine Whitbread as Director Against 16 Elect Jan du Plessis as Director Against Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018 BT Group plc Proposal Vote Number Proposal Text Instruction 17 Reappoint PricewaterhouseCoopers LLP as Withhold Auditors 18 Authorise Board to Fix Remuneration of For Auditors 19 Authorise Issue of Equity with Pre-emptive For Rights 20 Authorise Issue of Equity without Pre-emptive For Rights 21 Authorise Market Purchase of Ordinary Shares For 22 Authorise the Company to Call General For Meeting with Two Weeks' Notice 23 Authorise EU Political Donations
    [Show full text]
  • GSK Annual Report 2005 01 However, Addressing This Challenge Is Something GSK Cannot “The Tragedies During the Year Brought Home to Me the Extent Do Alone
    Annual Report 2005 Corporate Website brochure About us Meeting global challenges Our products Commitment to innovation Your health Access to medicines Responsibility Therapy areas In the community Our mission Research & Development A better future Investors What would Media centre you like to know Careers about GSK? www.gsk.com Corporate Annual GlaxoSmithKline Annual Report 2005 responsibility review report Access to medicines An interview with Research and innovation the Chairman and CEO human being Ethical conduct Focus on the patient Employees Annual The year of the vaccine Human rights Growing brands Environment report Powering performance Community investment Performance highlights Business operating review Summary remuneration report An interview with Corporate governance the Chairman and CEO Summary financial statements Financial summary Shareholder information Description of business Chairman and CEO’s Corporate governance closing letter Remuneration report Operating and financial review and prospects Financial statements Notes to the financial statements Investor information Do more, feel better, live longer Head Office and Registered Office GlaxoSmithKline plc 980 Great West Road Designed by CGI London. Brentford, Middlesex TW8 9GS Printed by The Midas Press in the UK. The paper used in the United Kingdom production of this document is made from pulps harvested Tel: +44 (0)20 8047 5000 from sustainable forests, also using sawmill residues and www.gsk.com forest thinnings. It is elemental chlorine-free. Do more, feel better, live longer “Discovering important medicines eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people This is what we do – and what we do matters to people.” JP Garnier (left) and Sir Christopher Gent (right) “Thanks to the efforts of our employees around the world, 2005 was a very successful year for GSK.
    [Show full text]